Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
- To determine if docetaxel and cisplatin can be administered in a dose intense manner in
the adjuvant setting in resected non-small cell lung cancer
- To evaluate the time to progression and overall survival
- To evaluate toxicities of this chemotherapy combination in the adjuvant setting
- To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in
patients treated with this regimen